Product Description
a liquid produced from Saccharomyces cerevisiae containing 6000 IU of sucrase activity per mg protein. Sacrosidase is a safe, effective, well-accepted treatment to prevent gastrointestinal symptoms in patients with CSID consuming a normal diet. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/9932843/)
Mechanisms of Action: Disaccharide Metabolizer
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Korea | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: QOL Medical
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Celiac Disease|Cross Infection|Protein Deficiency
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05703009 |
SSDXA-14 | P2 |
Completed |
Cross Infection|Celiac Disease|Protein Deficiency |
2024-01-22 |
14% |
2024-02-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |